TransMedics Group, Inc. (NASDAQ:TMDX) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have earned an average recommendation of “Moderate Buy” from the ten research firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $133.88.

A number of research firms recently issued reports on TMDX. Piper Sandler reiterated an “overweight” rating and issued a $120.00 target price on shares of TransMedics Group in a research note on Friday, June 21st. TD Cowen raised their price target on TransMedics Group from $130.00 to $175.00 and gave the company a “buy” rating in a research report on Friday, June 7th. Stephens began coverage on TransMedics Group in a research report on Tuesday, June 4th. They set an “overweight” rating and a $151.00 price objective for the company. Oppenheimer increased their target price on TransMedics Group from $105.00 to $125.00 and gave the company an “outperform” rating in a research note on Wednesday, May 1st. Finally, Cantor Fitzgerald initiated coverage on TransMedics Group in a research report on Thursday, June 6th. They issued an “overweight” rating and a $161.00 price target on the stock.

Insider Activity

In other TransMedics Group news, insider Tamer I. Khayal sold 63,260 shares of TransMedics Group stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $108.54, for a total transaction of $6,866,240.40. Following the sale, the insider now owns 9,792 shares in the company, valued at $1,062,823.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Waleed H. Hassanein sold 12,000 shares of the business’s stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $95.09, for a total value of $1,141,080.00. Following the sale, the chief executive officer now owns 74,087 shares in the company, valued at approximately $7,044,932.83. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Tamer I. Khayal sold 63,260 shares of the company’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $108.54, for a total transaction of $6,866,240.40. Following the completion of the sale, the insider now directly owns 9,792 shares in the company, valued at approximately $1,062,823.68. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 275,501 shares of company stock worth $32,158,039. Company insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rhumbline Advisers raised its stake in shares of TransMedics Group by 2.5% in the third quarter. Rhumbline Advisers now owns 46,595 shares of the company’s stock valued at $2,551,000 after acquiring an additional 1,123 shares during the last quarter. Envestnet Portfolio Solutions Inc. bought a new stake in shares of TransMedics Group during the third quarter worth $203,000. Envestnet Asset Management Inc. increased its stake in shares of TransMedics Group by 104.0% in the third quarter. Envestnet Asset Management Inc. now owns 80,752 shares of the company’s stock valued at $4,421,000 after buying an additional 41,168 shares in the last quarter. Qube Research & Technologies Ltd raised its holdings in shares of TransMedics Group by 31.2% in the third quarter. Qube Research & Technologies Ltd now owns 84,450 shares of the company’s stock valued at $4,624,000 after buying an additional 20,081 shares during the last quarter. Finally, Lazard Asset Management LLC lifted its position in TransMedics Group by 13,809.8% during the 3rd quarter. Lazard Asset Management LLC now owns 73,722 shares of the company’s stock worth $4,036,000 after buying an additional 73,192 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Trading Down 0.3 %

TransMedics Group stock opened at $150.19 on Tuesday. TransMedics Group has a one year low of $36.42 and a one year high of $154.14. The company’s fifty day moving average price is $132.28 and its two-hundred day moving average price is $100.08. The company has a market capitalization of $4.95 billion, a price-to-earnings ratio of -441.74 and a beta of 1.98. The company has a debt-to-equity ratio of 3.18, a current ratio of 9.72 and a quick ratio of 8.76.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Tuesday, April 30th. The company reported $0.35 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.40. TransMedics Group had a positive return on equity of 7.95% and a negative net margin of 3.43%. The business had revenue of $96.90 million for the quarter, compared to the consensus estimate of $83.78 million. During the same period last year, the business earned ($0.08) EPS. The firm’s revenue was up 132.9% compared to the same quarter last year. On average, analysts forecast that TransMedics Group will post 0.77 earnings per share for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.